share_log

Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $2

Benzinga ·  Mar 25 14:26

Scotiabank analyst Sung Ji Nam maintains Pacific Biosciences (NASDAQ:PACB) with a Sector Outperform and lowers the price target from $6 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 246

Recommended

Write a comment